Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
In the contemporary epidemiological landscape, Mycoplasma pneumoniae pneumonia (MPP) is witnessing a conspicuous surge within the pediatric demographic in China. Recent oscillations, marked by minor peaks and a distinct predilection toward younger age cohorts, have heightened apprehensions, particularly amidst a pronounced escalation in cases displaying heightened severity and refractoriness. This analytical endeavor seeks to meticulously unravel the intricate tapestry of the burgeoning MPP scenario, systematically dissecting the causative factors propelling this upward trajectory.Simultaneously, the distinctive characteristics of a younger age profile and an elevated proportion of severe and refractory cases prompt profound concerns regarding the prospective impact of respiratory diseases on the pediatric population in China in the ensuing years.
Down syndrome (DS) is the most common viable autosomal trisomy. The average lifespan of a person with DS is approximately 60 years and the infant mortality rate is about 5%. However, in this issue of Pediatric Research, Shimokaze et al. report that the mortality rate of infants with DS born at <34 weeks’ gestation is 40%. In addition, 84% of the infants who died had a history of non-reassuring fetal status (NRFS). Thus, fetuses with DS who develop NRFS at <34 weeks’ gestation may have significant challenges to their viability. The expansion of noninvasive prenatal genetic testing will increase the number of fetuses diagnosed with DS. Thus, we need to start discussions about suitable strategies for fetuses who are diagnosed as DS and have NRFS at <34 weeks’ gestation.